Jacobio Pharmaceuticals Group Management
Management criteria checks 3/4
Jacobio Pharmaceuticals Group's CEO is Yinxiang Wang, appointed in Aug 2019, has a tenure of 4.75 years. total yearly compensation is CN¥3.77M, comprised of 61.3% salary and 38.7% bonuses, including company stock and options. directly owns 13.58% of the company’s shares, worth HK$181.76M. The average tenure of the management team and the board of directors is 4.3 years and 4.8 years respectively.
Key information
Yinxiang Wang
Chief executive officer
CN¥3.8m
Total compensation
| CEO salary percentage | 61.3% |
| CEO tenure | 4.8yrs |
| CEO ownership | 13.6% |
| Management average tenure | 4.3yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely
May 10
Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook
Aug 26We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate
Jul 29We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth
Apr 29What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?
Mar 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -CN¥359m |
| Sep 30 2023 | n/a | n/a | -CN¥385m |
| Jun 30 2023 | n/a | n/a | -CN¥410m |
| Mar 31 2023 | n/a | n/a | -CN¥391m |
| Dec 31 2022 | CN¥4m | CN¥2m | -CN¥372m |
| Sep 30 2022 | n/a | n/a | -CN¥332m |
| Jun 30 2022 | n/a | n/a | -CN¥292m |
| Mar 31 2022 | n/a | n/a | -CN¥297m |
| Dec 31 2021 | CN¥4m | CN¥2m | -CN¥301m |
Compensation vs Market: Yinxiang's total compensation ($USD520.09K) is above average for companies of similar size in the Hong Kong market ($USD357.59K).
Compensation vs Earnings: Yinxiang's compensation has been consistent with company performance over the past year.
CEO
Yinxiang Wang (58 yo)
4.8yrs
Tenure
CN¥3,766,000
Compensation
Dr. Yinxiang Wang serves as Consultant at Shining Capital. He is an Executive Chairman at Jacobio Pharmaceuticals Co. Ltd. since August 20, 2020.Dr. Wang has been Director at Jacobio Pharmaceuticals Co. L...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 4.8yrs | CN¥3.77m | 13.58% CN¥ 181.8m | |
| Executive Director & President of Administration | 8.7yrs | CN¥2.86m | 2.9% CN¥ 38.8m | |
| Executive VP & Executive Director | 5.2yrs | CN¥2.84m | 2.94% CN¥ 39.4m | |
| Vice President of Human Resources | no data | no data | no data | |
| Executive VP | 3.8yrs | no data | no data | |
| Executive Vice President of Non-Clinical R&D | no data | no data | no data | |
| Senior Vice President of Information & Data Management | no data | no data | no data | |
| Head of Drug Discovery | no data | no data | no data | |
| Executive Vice President of Clinical Development | no data | no data | no data | |
| Joint Company Secretary | 3.8yrs | no data | no data | |
| Joint Company Secretary | 1.8yrs | no data | no data |
4.3yrs
Average Tenure
55yo
Average Age
Experienced Management: 1167's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 5.9yrs | CN¥3.77m | 13.58% CN¥ 181.8m | |
| Executive Director & President of Administration | 5.8yrs | CN¥2.86m | 2.9% CN¥ 38.8m | |
| Executive VP & Executive Director | 5.8yrs | CN¥2.84m | 2.94% CN¥ 39.4m | |
| Non-Executive Director | 5.8yrs | no data | no data | |
| Independent Non-Executive Director | 3.8yrs | CN¥200.00k | no data | |
| Independent Non-Executive Director | 3.8yrs | CN¥400.00k | no data | |
| Non Executive Director | 3.8yrs | no data | no data | |
| Independent Non-Executive Director | 1.2yrs | no data | no data |
4.8yrs
Average Tenure
58.5yo
Average Age
Experienced Board: 1167's board of directors are considered experienced (4.8 years average tenure).